Skip to content
Screener

Gilead Sciences GILD D&A

D&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$594M-41.2%
Incyte logo
IncyteINCY
$26.48M+15.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$4.38M+14.4%
Precigen logo
PrecigenPGEN
$1.1M+74.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$130K-11.0%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$3.78M+11.3%

Other financials

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%
EPS (diluted)-$8.45-642%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation

See full
Market cap$163.59B+19.3%
Enterprise value$186.66B+18.9%
P/S5.4×+0.6×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000882095-26-000031
(in millions)Three Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Depreciation expense$98$93$191$190

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's D&A?
Gilead Sciences (GILD) reported D&A of $98M in Q2 2026.
How has Gilead Sciences's D&A changed year-over-year?
Gilead Sciences's D&A increased by 5.4% year-over-year, from $93M to $98M.
What is the long-term trend for Gilead Sciences's D&A?
Over 4 years (2021 to 2025), Gilead Sciences's D&A has grown at a -5.4% compound annual growth rate (CAGR), from $1.72B to $1.38B.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Gilead Sciences's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude